Adicet Bio Future Growth

Future criteria checks 0/6

Adicet Bio is forecast to grow earnings and revenue by 7.1% and 64.3% per annum respectively while EPS is expected to grow by 12.8% per annum.

Key information

7.1%

Earnings growth rate

12.8%

EPS growth rate

Biotechs earnings growth21.1%
Revenue growth rate64.3%
Future return on equityn/a
Analyst coverage

Good

Last updated02 Apr 2024

Recent future growth updates

Recent updates

Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate

Feb 01
Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?

Dec 07
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?

Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?

Aug 07
Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Apr 20
Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Dec 20
Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio

Oct 17

Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?

Oct 04
Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?

Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term

Aug 16
Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term

Adicet Bio: A First Take

Jul 22

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Jul 07
Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit

May 15
Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit

We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Mar 18
We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate

Feb 09

Adicet: Promising 2021 Therapeutic Initiations, Cash Of $108 Million, And New Management

Dec 28

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Dec 16
Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Earnings and Revenue Growth Forecasts

NasdaqGM:ACET - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20266-124-95-1294
12/31/20254-125-89-1167
12/31/2024N/A-122-82-947
12/31/2023N/A-143-98-94N/A
9/30/2023N/A-143-100-89N/A
6/30/2023N/A-115-98-83N/A
3/31/2023N/A-105-89-73N/A
12/31/202225-70-62-45N/A
9/30/202230-56-53-39N/A
6/30/202234-48-49-34N/A
3/31/202239-36-47-32N/A
12/31/202110-62-64-51N/A
9/30/202110-55-61-51N/A
6/30/20219-56-52-49N/A
3/31/202112-54-50-48N/A
12/31/202018-37-43-42N/A
9/30/202014-34-37-35N/A
6/30/20204-34-36-35N/A
3/31/20200-28-30-29N/A
12/31/20191-28-29-28N/A
12/31/20188-9-19-18N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACET is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACET is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACET is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ACET is forecast to have no revenue next year.

High Growth Revenue: ACET is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ACET's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.